Retraction Remorse

The journal that published and abruptly retracted the first study linking the lab-made virus XMRV to disease apologizes to the authors.

Written byBeth Marie Mole
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Wikimedia Commons, Center for Disease Control and PreventionThe editors of PLOS Pathogens wish to atone for not warning all corresponding authors that they were retracting the 2006 study that first reported a link between a lab-made virus called XMRV and prostate cancer, according to a PLOS blog post by the editor-in-chief Kasturi Haldar last week (September 28).

“We have apologized for not contacting the second corresponding author,” Haldar wrote in the post. “Our expectation was that the first would discharge responsibilities to all remaining authors. We have since corresponded with all authors.”

Though the journal editors contacted the first corresponding author of the seminal 2006 XMRV paper, Joseph DeRisi of the University of California, San Francisco, he was unresponsive to their email messages, and they did not contact the second author, Robert Silverman of the Cleveland Clinic in Ohio. Silverman told ScienceInsider that he was “completely blindsided” by the retraction and said that he had been preparing an erratum he felt was sufficient to address the incorrect link between XMRV and prostate cancer.

“The discovery of XMRV, a new virus, still stands,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies